Evidence map›Paper›PMID 38561419›Full record

ArticleScientific reports2024

Tenovin 3 induces apoptosis and ferroptosis in EGFR 19del non small cell lung cancer cells.

Sha Lv, Qianrong Pan, Weijin Lu, Weisong Zhang, Naike Wang, Lijuan Huang, Lianjing Li, Jieyao Liu, Jiamei Ma, Zhan Li and 3 more

Erratum issuedAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Sha Lv *The Fifth Affiliated Hospital,Guangdong Province & NMPA & State Key Laboratory,School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, People's Republic of China.
Qianrong Pan *The Fifth Affiliated Hospital,Guangdong Province & NMPA & State Key Laboratory,School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, People's Republic of China.
Weijin Lu *The Fifth Affiliated Hospital of Jinan University (Heyuan Shenhe People's Hospital), Heyuan, 517000, China.
Weisong ZhangThe Fifth Affiliated Hospital,Guangdong Province & NMPA & State Key Laboratory,School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, People's Republic of China.
Naike WangGMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macau Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Medical University, Guangzhou, 511436, People's Republic of China.
Lijuan HuangThe Fifth Affiliated Hospital,Guangdong Province & NMPA & State Key Laboratory,School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, People's Republic of China.
Lianjing LiThe Fifth Affiliated Hospital,Guangdong Province & NMPA & State Key Laboratory,School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, People's Republic of China.
Jieyao LiuThe Fifth Affiliated Hospital,Guangdong Province & NMPA & State Key Laboratory,School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, People's Republic of China.
Jiamei MaMedicine and Health Science College, Guangzhou Huashang College, Guangzhou, People's Republic of China.
Zhan LiThe Fifth Affiliated Hospital,Guangdong Province & NMPA & State Key Laboratory,School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, People's Republic of China.
Yong HuangThe Fifth Affiliated Hospital,Guangdong Province & NMPA & State Key Laboratory,School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, People's Republic of China.
Qiudi DengGMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macau Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Medical University, Guangzhou, 511436, People's Republic of China. dengqiudi@gzhmu.edu.cn.
Xueping LeiThe Fifth Affiliated Hospital,Guangdong Province & NMPA & State Key Laboratory,School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, People's Republic of China. xuepinglei@gzhmu.edu.cn.

Funding

characteristic innovation project of Guangdong Provincial Education Department 2021KTSCX092National Natural Science Foundation of China 82104201the Medical Science and Technology Research Foundation of Guangdong Province A2022549the Traditional Chinese Medicine Program of Guangdong 20211066
6 · The paper itself

Abstract

Epidermal growth factor receptor (EGFR) exon 19 deletion is a major driver for the drug resistance of non-small cell lung cancer (NSCLC). Identification small inhibitor capable of selectively inhibiting EGFR-19del NSCLC is a desirable strategy to overcome drug resistance in NSCLC. This study aims to screen an inhibitor for EGFR exon 19 deletion cells and explore its underlying mechanism. High through-put screen was conducted to identify an inhibitor for EGFR-19del NSCLC cells. And tenovin-3 was identified as a selective inhibitor of PC9 cells, an EGFR-19del NSCLC cells. Tenovin-3 showed particular inhibition effect on PC9 cells proliferation through inducing apoptosis and ferroptosis. Mechanistically, tenovin-3 might induce the apoptosis and ferroptosis of PC9 cells through mitochondrial pathway, as indicated by the change of VDAC1 and cytochrome c (cyt c). And bioinformatics analyses showed that the expression levels of SLC7A11 and CPX4 were correlated with NSCLC patient's survival. Our findings provide evidences for tenovin-3 to be developed into a novel candidate agent for NSCLC with EGFR exon 19 deletion. Our study also suggests that inducing ferroptosis may be a therapeutic strategy for NSCLC with EGFR exon 19 deletion.

Indexed as

Antineoplastic AgentsCarcinoma, Non-Small-Cell LungFerroptosisLung NeoplasmsApoptosisCell Line, TumorDrug Resistance, NeoplasmErbB ReceptorsHumansMutationProtein Kinase InhibitorsAntineoplastic AgentsEGFR protein, humanErbB ReceptorsProtein Kinase InhibitorsApoptosisEpidermal growth factor receptor (EGFR) mutationFerroptosisNon-small cell lung cancer (NSCLC)Tenovin-3

Identifiers

PMID38561419
PMCPMC10985106

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.